U.S. Durable Medical Equipment Market Size, Share, and Growth Forecast 2026 - 2033

The U.S. durable medical equipment market is expected to be valued at US$ 74.40 Billion in 2026 and is projected to reach US$ 108.95 Billion, growing at a CAGR of 5.6% between 2026 and 2033. The U.S. durable medical equipment market is primarily driven by an aging demographic and the sustained federal policy commitment to home- and community-based care reimbursement.

The Centers for Medicare & Medicaid Services (CMS) remains the single most consequential demand driver, as its competitive bidding program and fee schedule updates directly influence reimbursement rates across most durable medical equipment categories. According to U.S. Census Bureau projections, Americans aged 65 and older are expected to account for nearly 22% of the total U.S. population by 2030, creating a strong demographic foundation for sustained demand for durable medical equipment.

Drivers - Accelerating Medicare Coverage Expansion for Home-Based DME

The expanding scope of Medicare reimbursement for home-based DME remains one of the primary demand drivers for market participants, as CMS's annual fee schedule updates have steadily broadened the range of reimbursable home DME categories, directly expanding the addressable patient population for suppliers. The Improving Seniors' Timely Access to Care Act, implemented in 2022, streamlined prior authorization for DME under Medicare Advantage, reducing approval delays that previously constrained the adoption of high-value equipment such as power wheelchairs and home oxygen concentrators.

Companies including Rotech Healthcare responded in 2023 by expanding home delivery fulfillment networks across Sun Belt states. Such regulatory momentum is expected to strengthen as Medicare Advantage enrollment, which surpassed 33 million beneficiaries, according to CMS data in 2024, continues shifting beneficiaries toward managed care plans that increasingly compete on DME access speed as a key differentiator.

Chronic Disease Prevalence Driving Multi-Device Household Demand

Rising chronic disease prevalence in the U.S. continues to boost DME utilization, as individuals managing comorbidities such as COPD, diabetes, and congestive heart failure often require respiratory, mobility, and patient monitoring equipment simultaneously. The Centers for Disease Control and Prevention (CDC) reported in its 2023 National Chronic Disease Data that around six in 10 U.S. adults live with at least one chronic disease, while four in 10 live with two or more. This significantly increases average DME expenditure per household across the care continuum.

Philips Respironics, despite its 2021 CPAP recall, processed millions of remediation device replacements through 2023 and 2024, illustrating the essential nature of respiratory DME demand even during major product disruptions. The ongoing replacement cycle is expected to reinforce demand for manufacturers maintaining reliable supply chains.

Restraints - Reimbursement Rate Compression Under CMS Competitive Bidding

CMS's Competitive Bidding Program, originally authorized under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 and expanded through successive rounds, continues to compress supplier margins by increasing price competition across standardized DME categories, limiting providers' ability to pass rising costs downstream. The Round 2021 Competitive Bidding Program established single payment amounts across 130 product categories in competitive bidding areas, with industry estimates indicating that reimbursement rates remained estimated at 40% to 50% below pre-bidding fee schedule levels for categories including enteral nutrition equipment and standard power wheelchairs.

For new entrants seeking regional expansion, maintaining profitability under this pricing environment depends on capital-efficient logistics and inventory management. Established national suppliers have already developed these capabilities, giving them a structural cost advantage over smaller operators.

Medical-Grade Supply Chain Vulnerabilities and Import Cost Exposure

U.S. DME manufacturers and distributors remain exposed to component cost volatility, particularly for products relying on medical-grade aluminum, lithium-ion battery cells, and electronic control modules, the majority of which originate from East Asian supply chains affected by ongoing trade policy uncertainty. The U.S. Trade Representative's Section 301 tariffs on Chinese-origin medical products, maintained and reviewed through 2024, imposed estimated cost premiums of 7.5% to 25% on selected DME components depending on product classification, directly reducing distributor margins for mid-tier mobility and respiratory equipment. Larger manufacturers with diversified supplier networks across Vietnam, Malaysia, and Mexico have reduced a portion of this exposure, while smaller distributors dependent on single-country sourcing continue to face higher landed costs that remain difficult to recover under fixed CMS reimbursement schedules.

Opportunities - Telehealth-Integrated Remote Monitoring Equipment for Chronic Care Management

Connected DME platforms integrated with remote patient monitoring technologies represent a significant growth opportunity as payers continue expanding reimbursement pathways for digitally monitored therapeutic devices. CMS finalized permanent reimbursement for Remote Physiologic Monitoring (RPM) under CPT codes 99453, 99454, and 99457, with the policy reinforced through the 2024 Medicare Physician Fee Schedule Final Rule, validating the commercial infrastructure supporting connected glucose monitors, cardiac monitors, and smart respiratory devices alongside traditional DME. Broader adoption is expected as manufacturers obtain FDA 510(k) clearance for connected device platforms and strengthen data integration with major electronic health record systems such as Epic and Oracle Health.

Home Healthcare DME Expansion Driven by Post-Acute Care Shift

The rapid shift from skilled nursing facility care toward home-based post-acute recovery continues to create substantial opportunities for home healthcare DME providers. The AARP Public Policy Institute's 2023 Home and Community Preferences Survey found that 77% of adults aged 50 and older strongly prefer to remain in their own homes, reinforcing sustained demand for hospital beds, patient lifts, and ambulatory aids in home healthcare settings. Apria Healthcare, acquired by Option Care Health in 2023, expanded its home infusion and respiratory therapy DME portfolio in response to this trend. Growing demand for integrated services is expected to benefit providers offering DME supply, clinical coordination, and insurance billing through a unified home healthcare model.

Product Insights

Personal mobility devices are projected to hold nearly 35.0% share of the U.S. durable medical equipment market in 2026. This dominance is attributed to their indispensable role across the full spectrum of mobility impairment, from post-surgical rehabilitation patients requiring crutches and walkers after acute-care discharge to individuals with permanent mobility limitations who depend on power wheelchairs for daily independence.

Veterans Affairs medical centers remain major institutional purchasers of custom power wheelchairs and prosthetic-adjacent mobility aids, with the U.S. Department of Veterans Affairs processing hundreds of thousands of mobility device prescriptions annually through its Prosthetics and Sensory Aids Service. In addition, rising orthopedic procedure volumes, including total knee and hip replacements, which the American Academy of Orthopaedic Surgeons projects to exceed 1.2 million combined annual procedures by 2030, continue generating recurring demand for personal mobility devices.

Monitoring and therapeutic devices represent the fastest-growing product segment, driven by the FDA's 2023 updated guidance on Non-Prescription Continuous Glucose Monitors (CGMs), which enabled the over-the-counter U.S. launch of Abbott's FreeStyle Libre 2 in 2024. The updated guidance expanded access to CGMs for an estimated 96 million prediabetic U.S. adults identified by the CDC, significantly increasing the potential user base for continuous monitoring devices. Rising adoption of remote patient monitoring, growing diabetes and prediabetes prevalence, and increasing demand for home-based disease management continue to strengthen demand for monitoring and therapeutic DME across the U.S.

End-User Insights

Hospitals are projected to hold around 33.0% of the U.S. durable medical equipment market share in 2026, driven by the need to equip inpatient units with therapeutic and mobility devices while also preparing patients for safe discharge to home or post-acute care settings. Large integrated health systems such as HCA Healthcare, which operates over 180 hospitals across the U.S., negotiate centralized DME procurement contracts that favor established national suppliers capable of meeting standardized formulary requirements and ensuring consistent product availability across regional facilities. Hospital-based DME utilization remains concentrated in ICU-grade therapeutic equipment, including ventilators, infusion pumps, and sequential compression devices, where standardized clinical protocols and Joint Commission accreditation requirements support recurring procurement from approved vendors.

Home healthcare represents the fastest-growing end-user segment, propelled by the Bipartisan Budget Act of 2018, which expanded Medicare home healthcare coverage criteria and steadily increased the number of homebound patients eligible for DME-supported care plans. Lincare Holdings expanded its home respiratory therapy and oxygen concentrator delivery network across rural and suburban areas during 2023 and 2024, reflecting the growing demand for home-based DME services.

The U.S. durable medical equipment market is moderately consolidated at the national distribution tier and highly fragmented at regional specialty levels. Medline Industries and Cardinal Health dominate institutional supply through GPO-aligned contracts and hospital system relationships, while Invacare Corporation anchors the mobility device manufacturing segment despite executing a financial restructuring completed in 2023. The dominant strategic theme among market leaders is vertical integration combining manufacturing, logistics, billing, and clinical services into unified platforms. Drive DeVilbiss Healthcare represents the most aggressive mid-tier disruptor, expanding its product breadth across mobility, respiratory, and daily living aids to challenge pure-play specialists on both price and breadth.

Key Industry Developments

• In February 2025, Supernus Pharmaceuticals announced that its SPN-830 branded as Onapgo, an infusion pump, bagged the approval of the U.S. FDA for the treatment of motor fluctuations in adults living with advanced Parkinson’s. The wearable pump was designed to offer a constant subcutaneous infusion of the company’s apomorphine (Apokyn).
• In September 2024, Abbott Laboratories introduced Lingo, its new over-the-counter continuous glucose monitor, in the U.S. It was designed for individuals who do not take insulin and want to enhance their health and well-being.